Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.

Barry, Houreratou; Mutua, Gaudensia; Kibuuka, Hannah; Anywaine, Zacchaeus; Sirima, Sodiomon B; Meda, Nicolas; Anzala, Omu; Eholie, Serge; Bétard, Christine; Richert, Laura; +14 more... Lacabaratz, Christine; McElrath, M Juliana; De Rosa, Stephen; Cohen, Kristen W; Shukarev, Georgi; Robinson, Cynthia; Gaddah, Auguste; Heerwegh, Dirk; Bockstal, Viki; Luhn, Kerstin; Leyssen, Maarten; Douoguih, Macaya; Thiébaut, Rodolphe; EBL2002 Study group; EBL2002 Study group; (2021) Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS medicine, 18 (10). e1003813-. ISSN 1549-1277 DOI: https://doi.org/10.1371/journal.pmed.1003813

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1371/journal.pmed.1003813

Abstract

Share

Download

Filename: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adult.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar